Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells

Grant Award Details

Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells

Grant Type: Discovery Research Projects

Grant Number: DISC2COVID19-12020

Project Objective: The objective of this award is to develop an allogeneic HSC-engineered iNKT (HSC-iNKT) cell therapy for treating COVID-19 patients.

Investigator:

Name:	Lili Yang
Institution:	University of California, Los Angeles
Type:	PI

Disease Focus: COVID-19, Infectious Disease

Human Stem Cell Use: Adult Stem Cell

Award Value: $250,000

Status: Pre-Active

Grant Application Details

Application Title: Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells

Public Abstract:

Research Objective

allogeneic HSC-engineered iNKT (HSC-iNKT) cells

Impact

treatment for COVID-19

Major Proposed Activities

- Milestone 1. Production of AlloHSC-iNKT and UHSC-iNKT cells
- Milestone 2. Characterization of the AlloHSC-iNKT and UHSC-iNKT cells
- Milestone 3. Delivery of the new therapeutic candidate

Statement of Benefit to California:	The novel SARS-CoV-2 is the cause of the coronavirus disease 19 (COVID-19) pandemic, which is responsible for over 10.3 million cases and 500,000 deaths worldwide. There are over 2.6 million COVID-19 cases in the US, including over 217,000 cases in California. The proposed off-the-shelf allogeneic HSC-engineered iNKT (HSC-iNKT) cell therapy, if successful, may provide a treatment and save lives of COVID-19 patients at California.

Source URL: https://www.cirm.ca.gov/our-progress/awards/battling-covid-19-using-shelf-hsc-engineered-inkt-cells